期刊文献+

美托洛尔与曲美他嗪联用治疗冠心病心力衰竭的疗效探讨 被引量:6

Effect of metoprolol and trimetazidine on heart failure with coronary heart disease
原文传递
导出
摘要 目的探讨曲美他嗪联合美托洛尔治疗冠心病心力衰竭患者的临床疗效。方法选取我院心内科2016年4月至2017年4月收治的冠心病心力衰竭患者84例,回顾性分析其临床资料,按照用药方式分成两组,各42例,其中对照组采用常规疗法,观察组基于对照组加用美托洛尔联合曲美他嗪,比较两组临床疗效。结果观察组总有效率为92.9%,明显高于对照组76.2%,比较差异明显(P<0.05);两组治疗前LVEDD、LVESD、LVEF及6min步行距离比较无明显差异(P>0.05),治疗后两组LVEDD、LVESD与治疗前相比均降低,LVEF、6min步行距离均升高;治疗后观察组LVEDD、LVESD均低于对照组,LVEF、6min步行距离优于对照组,比较差异均明显(P<0.05)。结论美托洛尔联合曲美他嗪可有效治疗冠心病心力衰竭,改善患者心功能,值得推广。 Objective To investigate the clinical efficacy of trimetazidine combined with metoprolol in the treatment of heart failure patients with coronary heart disease. Methods Select 84 eases of heart failure patients with coronary heart disease admitted from April 2016 to April 2017 in our hospital,retrospectively analyze the clinical data, divided into two groups according to the mode of administration, 42 cases in each group. The control group was treated by conventional therapy, Group based on the control group plus metoprolol combined with trimetazidine, the clinical efficacy of two groups were compared. Results The total effective rate in the observation group was 92.9%, significantly higher than 76.2% in the control group (P〈0.05). There was no significant difference in LVEDD, LVESD, LVEF and walking distance between the two groups before treatment (P〉O.05) The LVEDD and LVESD of the latter two groups were lower than those before treatment, and the walking distance of LVEF and 6min were both increased. After treatment, LVEDD and LVESD in the observation group were lower than those in the control group. LVEF and 6min walking distance were better than those in the control group (P〈0.05). Conclusion Metoprolol combined with trimetazidine can effectively treat heart failure in patients with coronary heart disease and improve cardiac function, which is worth promoting.
作者 孙桂枝 孔金明 Sun Guizhi;Kong Jinming(Department of Zhangjiakou City,Hebei Provine,the sixth hospital 075000,Chin)
出处 《中华心脏与心律电子杂志》 2016年第2期84-86,共3页 Chinese Journal of Heart and Heart Rhythm(Electronic Edition)
关键词 美托洛尔 曲美他嗪 冠心病心力衰竭 Metoprolol Trimetazidine Coronary Heart Disease Heart Failure
  • 相关文献

参考文献7

二级参考文献81

  • 1杨溶海,方长庚,梁建光.丹参多酚酸盐对冠心病心力衰竭患者左心功能及血清心型脂肪酸结合蛋白的影响[J].中国老年学杂志,2014,34(9):2322-2324. 被引量:38
  • 2赵自瑞 翟少军.曲美他嗪治疗冠心病心力衰竭患者121例临床分析.药物与临床,2010,5(17):59-60.
  • 3闫建萍.阿托伐他汀联合曲美他嗪治疗冠心病的疗效观察[J].实用心脑肺血管病杂志,2013,21 (1): 103.
  • 4Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart dis- ease, heart failure, and mortality in the atherosclerosis risk in communities study [J]. Circulation, 2011, 123 (13).- 1367- 1376.
  • 5Butler J. An overview of chronic heart failure management[J]. Nurs Times,2012,108(14-15) : 16-20.
  • 6Dedkova EN, Seidlmayer LK, Blatter LA. Mitochondria media- ted cardioprotection by trimetazidine in rabbit heart failure[J]. J Mol Cell Cardiol, 2018, 59=41-54.
  • 7Zhang L, Lu Y,Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis [J]. Am Coil Cardiol, 2012, 59(10) :913 922.
  • 8ITO H,NAGATOMO Y,KOHNO T,et al.Differential effects of carvedilol and metoprolol on renal function in patients with heart failure[J].Circ J,2010,74(8):1578-1583.
  • 9DU Y,YAN L,WANG J,et al.β1-Adrenoceptor autoantibodies from DCM patients enhance the proliferation of T lymphocytes through theβ1-AR/c AMP/PKA and p38 MAPK pathways[J].PLo S One,2012,7(12):e52911.
  • 10王勇.前列地尔对冠心病心力衰竭患者心功能及内皮细胞功能的影响[J].山东医药,2009,49(33):63-64. 被引量:20

共引文献590

同被引文献48

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部